Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 7/20 | 0.54 |
| ▸ | TEK | Q02763 | 7/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13979292 | 0.86 | BRAF (0.61) | BRAFRAF1LCKTEKKDR | |
| SCHEMBL3645004 | 0.85 | BRAF (0.55) | BRAFRAF1LCKTEKKDR | |
| SCHEMBL3643409 | 0.82 | BRAF (0.64) | BRAFRAF1LCKTEKKDR | |
| SCHEMBL3768730 | 0.80 | BRAF (0.66) | BRAFRAF1LCKTEKKDR | |
| SCHEMBL3770455 | 0.78 | BRAF (0.51) | BRAFRAF1LCKTEKKDR | |
| Ammonia Solution, Strong SCHEMBL3776283 | 0.77 | BRAF (0.55) | BRAFRAF1LCKTEKKDR | |
| SCHEMBL2268467 | 0.75 | TEK (0.76) | BRAFRAF1LCKTEKKDR | |
| SCHEMBL2262883 | 0.75 | BRAF (0.77) | BRAFRAF1LCKTEKKDR | |
| SCHEMBL3637714 | 0.74 | BRAF (0.53) | BRAFRAF1LCKTEKKDR | |
| SCHEMBL23015906 | 0.72 | BRAF (0.56) | BRAFRAF1LCKTEKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2170887-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008153947-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153947-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885LCK 337/4885 |
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885LCK 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.